Browsing Tag
Cosentyx
4 posts
How pediatric biologic approvals are transforming hidradenitis suppurativa treatment
Novartis AG expands Cosentyx approval to adolescents with hidradenitis suppurativa. Discover what this means for dermatology biologics and investors.
March 16, 2026
Novartis achieves 22% rise in core operating income, driven by innovative medicines
Novartis has reported a stellar performance for the fourth quarter of 2024, showcasing impressive growth across its core…
February 9, 2025
FDA approves Novartis’ Cosentyx for hidradenitis suppurativa treatment
Novartis, a global leader in immuno-dermatology and rheumatology, announced the U.S. Food and Drug Administration’s approval of Cosentyx…
November 1, 2023
EC approves dosing flexibility for Novartis’s Cosentyx in psoriatic arthritis treatment
The European Commission (EC) has granted Novartis approval for a significant update to the label of its psoriatic…
October 28, 2018